We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Assess an Auto-injector Being Used to Treat a Migraine Attack

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00510419
First Posted: August 2, 2007
Last Update Posted: June 8, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Pfizer
  Purpose

The purpose of this research study is to evaluate an investigational auto-injector system for delivering sumatriptan under the skin for a single migraine attack.

The study could take approximately 5 weeks and will include about 3 office visits to the study doctor, the patient will be contacted every 2 weeks until the patient experiences a migraine and uses the auto-injector. The last visit will be done by a telephone follow-up call.


Condition Intervention Phase
Migraine Drug: "Investigational"Auto-injector (sumatriptan succinate) Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3 Open-Label Study to Assess Subcutaneous Self-Injection With Sumatriptan Succinate Using an Auto-injector During a Single Migraine Attack

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Successful administration and acceptability of self-injection of sumatriptan under the skin using an investigational auto-injector will be assessed by use of patient-completed scales and a short questionnaire.

Secondary Outcome Measures:
  • • Comparison of pain scores pre-dose and 2 hours post-dose. • Preference of investigational auto-injector experience compared to subject's previous self-administration of sumatriptan.

Enrollment: 73
Study Start Date: July 2007
Study Completion Date: December 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Detailed Description:

Investigational Plan:

  1. Screening Visit [Visit 0 / 0-14 days prior to receipt of study drug]
  2. Baseline Visit [Visit 1 / Provision of study drug and subject training]
  3. Treatment Visit [Visit 2 / within 72 hours after study drug administration]
  4. Follow-up Visit [Visit 3 / Telephone follow-up 7-10 days after study drug administration]
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Adults 18 to 60 years of age
  2. Prior effective use of injectable sumatriptan on at least two occasions within the last two months
  3. At least two migraines per month suitable injectable sumatriptan
  4. Capable of using a migraine self-injection auto-injector
  5. Capable of distinguishing between migraine and other headache types (e.g., tension-type headache)

Exclusion Criteria:

  1. Seizure disorders
  2. Coronary artery disease (CAD)
  3. Cardiac dysrhythmia or pacemaker
  4. High blood pressure
  5. Liver disease
  6. Kidney disease
  7. Autoimmune disease
  8. History of alcohol or substance abuse
  9. Currently pregnant
  10. Use of any other investigational drug product within 30 days prior to treatment visit
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00510419


Locations
United States, California
San Francisco Clinical Research Center
San Francisco, California, United States, 94109
United States, Connecticut
New England Center for Headache
Stamford, Connecticut, United States, 06902
United States, Illinois
Diamond Head Clinic
Chicago, Illinois, United States, 60614
United States, Michigan
Michigan Head Pain & Neurological Institute
Ann Arbor, Michigan, United States, 48104
United States, Missouri
Clinvest
Springfield, Missouri, United States, 65807
United States, Pennsylvania
University of Pittsburgh Headache Center
Pittsburgh, Pennsylvania, United States, 15213
United States, Tennessee
Wesley Headache Clinic
Memphis, Tennessee, United States, 38018
United States, Texas
Anodyne Headache and Pain Care
Dallas, Texas, United States, 75231
Houston Headache Clinic
Houston, Texas, United States, 77004
Road Runner Research, LTD
San Antonio, Texas, United States, 78258
Sponsors and Collaborators
Pfizer
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00510419     History of Changes
Other Study ID Numbers: K644-07-3001
First Submitted: August 1, 2007
First Posted: August 2, 2007
Last Update Posted: June 8, 2012
Last Verified: June 2012

Keywords provided by Pfizer:
Migraine

Additional relevant MeSH terms:
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Sumatriptan
Vasoconstrictor Agents
Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs